Intermediate and Advanced Hepatoma
Conditions
Interventions
A:Treatment group: cinobufotalin injection 60ml+40% LIP 5-20ml obstructed
B:Control group: Epirubicin 40mg+40% Lipiodol 5-20ml blocked
Sponsors
Department of TCM, Changhai Hospital of Shanghai
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female; age: 18-70 years old ; 2. The patients have inoperable advanced hepatoma without serious disorders in liver and renal, tumor occupation 6 months, can tolerate TACE and quality of life ECOG score<3; 7. The patients participate the clinical trial voluntarily and have already signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Main portal vein obstructed completely; 2. The occupation of tumour are 70 % or more than 70 % in the whole liver; 3. The patient has received TACE or other anti-tumor therapy; 4. Receive prophylactic TACE after after carcinosectomy; 5. With renal insufficiency: Cr>=133 umol/L; 6. With severe cardiovascular disease; 7. With other diseases that may influence the therapy regimen; 8. With massive metastasis or combined with other malignant neoplastic disease; 9. Participate in other clinical trials; 10. Pregnant or breast-feeding females; allergic to the tested drugs or with contraindications to the drugs used in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The evaluation of the pre-therapy baseline of the patient (CT or MRI examination is carried out in treatment); | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic and Renal Function, AFP; | — |
Countries
China
Contacts
Public ContactChangquan Ling
Outcome results
None listed